Inocras Inc., a global leader in whole-genome sequencing (WGS) and bioinformatics, has announced the signing of a Memorandum of Understanding (MoU) with ChiMei Medical Center (CMMC), a premier medical institution in Taiwan, and Trivator Biomedical, a biomedical advisory firm in Taiwan.
This expansion agreement aims to introduce Inocras’s MRDVision tumour-informed minimal residual disease (MRD) test, utilising circulating tumour DNA (ctDNA) blood samples, and CancerVision, its artificial intelligence (AI)-powered bioinformatics cloud solution, to support WGS at CMMC, advancing Taiwan’s precision oncology landscape.
This initiative brings together CMMC’s in-house WGS laboratory infrastructure with Inocras’s advanced bioinformatics and ctDNA analysis platforms, creating a synergistic ecosystem for both research and clinical-grade genomics.
The integration of MRDVision’s ultra-sensitive ctDNA monitoring with CancerVision’s scalable cloud analytics enables an end-to-end workflow, from sequencing to interpretation, within CMMC’s existing clinical operations.
Powered by Ultima Genomics’ ppmSeq technology and Inocras’s bioinformatics platform, MRDVision identified tumour signals in 6% of cases missed by a leading MRD assay in a head-to-head clinical study of post-surgical ovarian and lung cancer patients. Integrated into CMMC’s sequencing and clinical workflows, CancerVision and MRDVision together provide an end-to-end solution for genome-informed cancer monitoring and personalised treatment assessment.
